论文信息 - Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC). - 字舞流文

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).

P. Bogner | P. Kufer | T. Raum | B. Rattel | O. Thomas | J. Wahl | A. Coxon | P. Deegen | Doris Rau | J. Bailis | Virginie Nägele | Shyun Li | Katja Matthes | M. Liao